{"id":40362,"date":"2026-11-16T09:28:53","date_gmt":"2026-11-16T08:28:53","guid":{"rendered":"https:\/\/ggba.swiss\/?p=40362"},"modified":"2026-11-16T09:28:53","modified_gmt":"2026-11-16T08:28:53","slug":"neurosterix-raises-usd-105-million-in-series-b-funding","status":"publish","type":"post","link":"https:\/\/ggba.swiss\/en\/neurosterix-raises-usd-105-million-in-series-b-funding\/","title":{"rendered":"Neurosterix raises USD 105 million in Series B funding"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><a href=\"https:\/\/neurosterix.com\/\">Neurosterix<\/a> has closed a USD 105 million Series B round led by <a href=\"https:\/\/www.rtwfunds.com\/\">RTW Investments<\/a>. New investors <a href=\"https:\/\/www.janushenderson.com\/\">Janus Henderson Investors<\/a>, <a href=\"https:\/\/www.gv.com\/\">GV<\/a>, <a href=\"https:\/\/ikariancapital.com\/\">Ikarian Capital<\/a>, <a href=\"https:\/\/www.linkedin.com\/company\/affinityassetadvisors\/\">Affinity Asset Advisors<\/a> and <a href=\"https:\/\/www.dellora.com\/\">Dellora Investments<\/a> joined the round, alongside existing investors <a href=\"https:\/\/www.perceptivelife.com\/\">Perceptive Advisors<\/a> and <a href=\"http:\/\/www.acornbioventures.com\/\">Acorn Bioventures<\/a>.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The funding will mainly advance NTX-253 into a phase 2 trial in schizophrenia and support the company&#8217;s broader portfolio of selective allosteric modulators for neuropsychiatric disorders. Neurosterix was spun out of <a href=\"https:\/\/www.addextherapeutics.com\/en\/\">Addex Therapeutics<\/a> in 2024 and launched with USD 63 million.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\">A pipeline built on allosteric modulation<\/h4>\n\n\n\n<p class=\"wp-block-paragraph\">NTX-253, the lead program, is a brain-penetrant, selective positive allosteric modulator of the M4 muscarinic receptor, a clinically validated target in schizophrenia. It has completed phase 1 single and multiple ascending dose studies, and pharmacokinetic data support once-daily oral dosing.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">NTX-819 is a potentially first-in-class negative allosteric modulator of the mGlu7 receptor, with preclinical results in models related to stress, mood and aggression. NTX-529 is a second M4 positive allosteric modulator, aimed at psychosis- and mood-related disorders. Behind the pipeline, Neurosterix holds a proprietary library of more than 80,000 compounds, more than 200 functional CNS assays and more than 100 patent filings.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Geneva-based Neurosterix, a clinical-stage biotech spun out of Addex Therapeutics in 2024, has closed a USD 105 million Series B round led by RTW Investments to advance NTX-253 into a phase 2 trial in schizophrenia.<\/p>\n","protected":false},"author":6,"featured_media":40363,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"mc4wp_mailchimp_campaign":[],"footnotes":""},"categories":[833],"tags":[894,890,940,886],"class_list":["post-40362","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-life-science","tag-financing","tag-healthcare","tag-neuroscience","tag-rd"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.7 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Neurosterix raises USD 105 million in Series B | GGBa<\/title>\n<meta name=\"description\" content=\"Geneva-based Neurosterix raises USD 105 million in Series B to advance NTX-253 into a phase 2 trial in schizophrenia.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ggba.swiss\/en\/neurosterix-raises-usd-105-million-in-series-b-funding\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Neurosterix raises USD 105 million in Series B | GGBa\" \/>\n<meta property=\"og:description\" content=\"Geneva-based Neurosterix raises USD 105 million in Series B to advance NTX-253 into a phase 2 trial in schizophrenia.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ggba.swiss\/en\/neurosterix-raises-usd-105-million-in-series-b-funding\/\" \/>\n<meta property=\"og:site_name\" content=\"Greater Geneva Bern area\" \/>\n<meta property=\"article:published_time\" content=\"2026-11-16T08:28:53+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ggba.swiss\/app\/uploads\/2026\/11\/Neurosterix-105-million-1180x811-1.jpeg\" \/>\n\t<meta property=\"og:image:width\" content=\"1180\" \/>\n\t<meta property=\"og:image:height\" content=\"811\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Pierre-Yves Oehrli\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Pierre-Yves Oehrli\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/ggba.swiss\\\/en\\\/neurosterix-raises-usd-105-million-in-series-b-funding\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/ggba.swiss\\\/en\\\/neurosterix-raises-usd-105-million-in-series-b-funding\\\/\"},\"author\":{\"name\":\"Pierre-Yves Oehrli\",\"@id\":\"https:\\\/\\\/staging.ggba.swiss\\\/en\\\/#\\\/schema\\\/person\\\/0b2e6d04131e3d01237dcb741fa33d41\"},\"headline\":\"Neurosterix raises USD 105 million in Series B funding\",\"datePublished\":\"2026-11-16T08:28:53+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/ggba.swiss\\\/en\\\/neurosterix-raises-usd-105-million-in-series-b-funding\\\/\"},\"wordCount\":189,\"image\":{\"@id\":\"https:\\\/\\\/ggba.swiss\\\/en\\\/neurosterix-raises-usd-105-million-in-series-b-funding\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/ggba.swiss\\\/app\\\/uploads\\\/2026\\\/11\\\/Neurosterix-105-million-1180x811-1.jpeg\",\"keywords\":[\"Financing\",\"Healthcare\",\"Neuroscience\",\"R&amp;D\"],\"articleSection\":[\"Life sciences\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/ggba.swiss\\\/en\\\/neurosterix-raises-usd-105-million-in-series-b-funding\\\/\",\"url\":\"https:\\\/\\\/ggba.swiss\\\/en\\\/neurosterix-raises-usd-105-million-in-series-b-funding\\\/\",\"name\":\"Neurosterix raises USD 105 million in Series B | GGBa\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/staging.ggba.swiss\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/ggba.swiss\\\/en\\\/neurosterix-raises-usd-105-million-in-series-b-funding\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/ggba.swiss\\\/en\\\/neurosterix-raises-usd-105-million-in-series-b-funding\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/ggba.swiss\\\/app\\\/uploads\\\/2026\\\/11\\\/Neurosterix-105-million-1180x811-1.jpeg\",\"datePublished\":\"2026-11-16T08:28:53+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/staging.ggba.swiss\\\/en\\\/#\\\/schema\\\/person\\\/0b2e6d04131e3d01237dcb741fa33d41\"},\"description\":\"Geneva-based Neurosterix raises USD 105 million in Series B to advance NTX-253 into a phase 2 trial in schizophrenia.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/ggba.swiss\\\/en\\\/neurosterix-raises-usd-105-million-in-series-b-funding\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/ggba.swiss\\\/en\\\/neurosterix-raises-usd-105-million-in-series-b-funding\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/ggba.swiss\\\/en\\\/neurosterix-raises-usd-105-million-in-series-b-funding\\\/#primaryimage\",\"url\":\"https:\\\/\\\/ggba.swiss\\\/app\\\/uploads\\\/2026\\\/11\\\/Neurosterix-105-million-1180x811-1.jpeg\",\"contentUrl\":\"https:\\\/\\\/ggba.swiss\\\/app\\\/uploads\\\/2026\\\/11\\\/Neurosterix-105-million-1180x811-1.jpeg\",\"width\":1180,\"height\":811,\"caption\":\"Neurosterix develops treatments for neuropsychiatric disorders, such as schizophrenia, by fine-tuning brain signaling. | \u00a9 Neurosterix\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/ggba.swiss\\\/en\\\/neurosterix-raises-usd-105-million-in-series-b-funding\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/ggba.swiss\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Neurosterix raises USD 105 million in Series B funding\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/staging.ggba.swiss\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/staging.ggba.swiss\\\/en\\\/\",\"name\":\"Greater Geneva Bern area\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/staging.ggba.swiss\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/staging.ggba.swiss\\\/en\\\/#\\\/schema\\\/person\\\/0b2e6d04131e3d01237dcb741fa33d41\",\"name\":\"Pierre-Yves Oehrli\",\"url\":\"https:\\\/\\\/ggba.swiss\\\/en\\\/author\\\/pierre-yves-oehrli\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Neurosterix raises USD 105 million in Series B | GGBa","description":"Geneva-based Neurosterix raises USD 105 million in Series B to advance NTX-253 into a phase 2 trial in schizophrenia.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ggba.swiss\/en\/neurosterix-raises-usd-105-million-in-series-b-funding\/","og_locale":"en_US","og_type":"article","og_title":"Neurosterix raises USD 105 million in Series B | GGBa","og_description":"Geneva-based Neurosterix raises USD 105 million in Series B to advance NTX-253 into a phase 2 trial in schizophrenia.","og_url":"https:\/\/ggba.swiss\/en\/neurosterix-raises-usd-105-million-in-series-b-funding\/","og_site_name":"Greater Geneva Bern area","article_published_time":"2026-11-16T08:28:53+00:00","og_image":[{"width":1180,"height":811,"url":"https:\/\/ggba.swiss\/app\/uploads\/2026\/11\/Neurosterix-105-million-1180x811-1.jpeg","type":"image\/jpeg"}],"author":"Pierre-Yves Oehrli","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Pierre-Yves Oehrli","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/ggba.swiss\/en\/neurosterix-raises-usd-105-million-in-series-b-funding\/#article","isPartOf":{"@id":"https:\/\/ggba.swiss\/en\/neurosterix-raises-usd-105-million-in-series-b-funding\/"},"author":{"name":"Pierre-Yves Oehrli","@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41"},"headline":"Neurosterix raises USD 105 million in Series B funding","datePublished":"2026-11-16T08:28:53+00:00","mainEntityOfPage":{"@id":"https:\/\/ggba.swiss\/en\/neurosterix-raises-usd-105-million-in-series-b-funding\/"},"wordCount":189,"image":{"@id":"https:\/\/ggba.swiss\/en\/neurosterix-raises-usd-105-million-in-series-b-funding\/#primaryimage"},"thumbnailUrl":"https:\/\/ggba.swiss\/app\/uploads\/2026\/11\/Neurosterix-105-million-1180x811-1.jpeg","keywords":["Financing","Healthcare","Neuroscience","R&amp;D"],"articleSection":["Life sciences"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/ggba.swiss\/en\/neurosterix-raises-usd-105-million-in-series-b-funding\/","url":"https:\/\/ggba.swiss\/en\/neurosterix-raises-usd-105-million-in-series-b-funding\/","name":"Neurosterix raises USD 105 million in Series B | GGBa","isPartOf":{"@id":"https:\/\/staging.ggba.swiss\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/ggba.swiss\/en\/neurosterix-raises-usd-105-million-in-series-b-funding\/#primaryimage"},"image":{"@id":"https:\/\/ggba.swiss\/en\/neurosterix-raises-usd-105-million-in-series-b-funding\/#primaryimage"},"thumbnailUrl":"https:\/\/ggba.swiss\/app\/uploads\/2026\/11\/Neurosterix-105-million-1180x811-1.jpeg","datePublished":"2026-11-16T08:28:53+00:00","author":{"@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41"},"description":"Geneva-based Neurosterix raises USD 105 million in Series B to advance NTX-253 into a phase 2 trial in schizophrenia.","breadcrumb":{"@id":"https:\/\/ggba.swiss\/en\/neurosterix-raises-usd-105-million-in-series-b-funding\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ggba.swiss\/en\/neurosterix-raises-usd-105-million-in-series-b-funding\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/ggba.swiss\/en\/neurosterix-raises-usd-105-million-in-series-b-funding\/#primaryimage","url":"https:\/\/ggba.swiss\/app\/uploads\/2026\/11\/Neurosterix-105-million-1180x811-1.jpeg","contentUrl":"https:\/\/ggba.swiss\/app\/uploads\/2026\/11\/Neurosterix-105-million-1180x811-1.jpeg","width":1180,"height":811,"caption":"Neurosterix develops treatments for neuropsychiatric disorders, such as schizophrenia, by fine-tuning brain signaling. | \u00a9 Neurosterix"},{"@type":"BreadcrumbList","@id":"https:\/\/ggba.swiss\/en\/neurosterix-raises-usd-105-million-in-series-b-funding\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ggba.swiss\/en\/"},{"@type":"ListItem","position":2,"name":"Neurosterix raises USD 105 million in Series B funding"}]},{"@type":"WebSite","@id":"https:\/\/staging.ggba.swiss\/en\/#website","url":"https:\/\/staging.ggba.swiss\/en\/","name":"Greater Geneva Bern area","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/staging.ggba.swiss\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41","name":"Pierre-Yves Oehrli","url":"https:\/\/ggba.swiss\/en\/author\/pierre-yves-oehrli\/"}]}},"_links":{"self":[{"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/posts\/40362","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/comments?post=40362"}],"version-history":[{"count":1,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/posts\/40362\/revisions"}],"predecessor-version":[{"id":40366,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/posts\/40362\/revisions\/40366"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/media\/40363"}],"wp:attachment":[{"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/media?parent=40362"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/categories?post=40362"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/tags?post=40362"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}